116247-91-7

Usage

Uses

Used in Pharmaceutical Industry:
8-(Pyrimidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane is used as a potential active pharmaceutical ingredient for its possible biological activity. The presence of a pyrimidine ring, which is common in many biologically active molecules, suggests that 8-(pyriMidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane could have therapeutic effects.
Used in Medicinal Chemistry Research:
8-(Pyrimidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane is used as a subject of study in medicinal chemistry to explore its chemical properties and potential interactions with biological targets, which could lead to the development of new drugs.
Used in Drug Development:
8-(Pyrimidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane is utilized in the drug development process to investigate its potential as a lead compound for the creation of new pharmaceuticals, given its unique structural features and the possibility of unique pharmacological properties.
Further research and exploration of 8-(pyriMidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane's chemical and biological properties are necessary to fully understand its potential applications and to harness its capabilities in the pharmaceutical field.

Upstream product

• 1722-12-9 2-chloropyrimidine 
• 584-08-7 potassium carbonate 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 4595-60-2 2-bromopyrimidine 

Relevant academic research and scientific papers

Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.

Pyrazolo(4,3-c)quinolines

There are disclosed compounds of the formula STR1 wherein the various substituents are defined hereinbelow, and, by virtue of their ability to inhibit interleukin 1, their use as antiinflammatory agents and in treatment of disease states involving enzymat

2-heterocyclobenzo[B][1,6]naphthyridines as inhibitors of interleukin

There are disclosed compounds of the formula STR1 wherein R1 is pyridl, quinolinyl, pyrazinyl, pyridinyl, pyridazinyl, pyrimidinyl, quinoxalinyl, quinazolinyl or any of the foregoing substituted with halo, lower alkyl, lower alkyl carbonyl, ben